ÌÇÐÄvlog´«Ã½ researchers collaborating with partners to develop novel drug therapy to potentially slow ALS

Two researchers from ÌÇÐÄvlog´«Ã½ are collaborating with colleagues at the Research Institute of the McGill University Health Centre (The Institute) and Neurodyn Life Sciences Inc., a PEI-based biotechnology company, on a project to develop a novel therapy to slow, or potentially functionally stabilize, the progression of amyotrophic lateral sclerosis (ALS).